To order this 310+page report, which features 170+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
The USD 2.8 billion (by 2030)financial opportunity within the STING pathway targeting technologies markethas been analysed across the following segments:
§ Types of Payment
§ Upfront Payments
§ Milestone Payments
§ Type of STINGModulator
§ Agonist
§ Antagonist
§ Key TherapeuticArea(s)
§ Oncological Disorders
§ InflammatoryDisorders
§ Infectious Diseases
§ Others
§ Route ofAdministration
§ Intratumoral
§ Intravenous
§ Oral
§ Subcutaneous
§ Others
§ Type of Molecule
§ Non-nucleotide
§ Cyclic Dinucleotide
§ Live Biotherapeutics
§ Oncolytic Peptides
§ Synthetic Peptides
§ Others
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia-Pacific
The STINGPathway Targeting Therapeutics and Technologies,2020-2030. report features thefollowing companies, which we identified to be key players in this domain:
§ Aduro Biotech
§ Bristol Myers Squibb
§ Eisai
§ GlaxoSmithKline
§ ImmuneSensor Therapeutics
§ Merck
§ Noxopharm
§ Spring Bank Pharmaceuticals
§ Synlogic
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. STING Pathway Targeting Therapeutics: CurrentMarket Landscape
5. STING Pathway Targeting Technologies: Current Market landscape
6. Company Profiles
7. Academic Grant Analysis
8. STING Related Initiatives of Big Pharmaceutical Players
9. Start-up Health Indexing
10. Publication Analysis
11. Partnerships and Collaborations
12. Funding and Investment Analysis
13. Market Sizing and Opportunity Analysis
14. Executive Insights
15. Concluding Remarks
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
